| Objective:Folate is closely related to the development of trace elements andtumorigenesis, homocysteine (Hcy) is an intermediate in the metabolismof folate, vitamin B12(VB12) as a coenzyme involved in folate metabolicprocesses, their carcinogenic effects causing broad enough attention.Recent studies on the relationship between folate, Hcy and VB12andtumor in domestic, but direct the few studies of relationship withprostate cancer.To determin serum folate, Hcy and VB12concentrations in prostatecancer group, benign prostatic hyperplasia（BPH）group, the healthycontrol group. Determine the relevant of serum folate, Hcy and VB12concen-trations and risk of prostate cancer in elderly. It can reveal therelationship between serum folate, Hcy and VB12and risk of prostatecancer in elderly.Methods:The study population included45patients with prostate cancerfrom First Hospital of Jilin University Urology, the range of age60~86years;45patients with benign prostatic hyperplasia from First Hospitalof Jilin University Urology, the range of age63~89years;45cases of healthy male healthy men from the First Hospital of Jilin University, andthe range of age58~83years. To determin serum folate, Hcy and VB12concentrations, To compare the concentrations of chemicals in threegroups by statistical methods. Determine the relevant of serum folate,Hcy and VB12concentrations and risk of prostate cancer in elderly.Results:1. prostate cancer group serum folate concentration (13.16±3.35nmol/L) is higher than the BPH group (9.44±2.54nmol/L) and healthycontrols (10.33±2.21nmol/L), the difference was statisticallysignificant, F=22.649,P＜0.05. Prostate cancer group serum Hcyconcentration (9.63±2.71μmol/L) lower than that of BPH group (12.60±2.26μmol/L) and healthy controls (11.98±1.67μmol/L), thedifference was statistically significant, F=21.857, P＜0.05. Prostatecancer group (327.81±124.40pmol/L), BPH group (295.86±101.34pmol/L), the healthy control group (282.61±102.36pmol/L), serumVB12concentration among the three groups difference was notstatistically significant, F=2.013, P＞0.05. BPH group compared withthe healthy control group, serum folate, Hcy, VB12concentrations wasnot statistically significant.2.The association of serum folate, Hcy and VB12concentrationswere in prostate cancer, benign prostatic hyperplasia, the healthy controlgroup, the relationship between the three groups the results show: folateare negatively correlated with Hcy (prostate cancer group P＜0.05,r=-0.849; BPH group P＜0.05, r=-0.468; healthy control group P＜0.05, r=-0.442).3. logistic regression analysis serum folate concentration positivelycorrelated with prostate cancer; serum Hcy concentration werenegatively correlated with prostate cancer; VB12in the serumconcentration of prostate cancer and no significant correlation.In comparison prostate patients and healthy controls group, andmales with the lowest tertile of serum folate, Hcy, VB12concentrationscompared to those in the middle tertile, The odds ratios(OR)were2.750（95%CI0.713～10.605, P＞0.05）;0.111（95%CI0.032～0.390, P＜0.05）;1.083（95%CI0.375～3.133, P＞0.05）; compared to those in thehighest tertile,The odds ratios(OR) were7.500(95%CI2.116~26.577,P＜0.05);0.139(95%CI0.043~0.451, P＜0.05);1.667(95%CI0.606~4.586, P＞0.05).In comparison prostate patients and BPH group, and males with thelowest tertile of serum folate, Hcy, VB12concentrations compared tothose in the middle tertile, The odds ratios ratios(OR)were3.850（95%CI1.026～14.446, P＜0.05）;0.131（95%CI0.035～0.486, P＜0.05）;0.741（95%CI0.258～2.129, P＞0.05）; compared to those in the highesttertile, The odds ratios(OR)were17.50（95%CI4.754～64.415, P＜0.05）;0.086（95%CI0.027～0.275, P＜0.05）;1.667（95%CI0.583～4.764, P＞0.05）。 Conclusion:1. Serum folate is a risk factor for prostate cancer.2. Serum Hcy is a risk factor for prostate cancer.3. Serum folate and prostate cancer was positively correlated;SerumHcy was negatively correlated with prostate cancer; Detection offolate,Hcy levels have significance for prostate cancer prevention. |
PDF Full Text Request